Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00916474 · ClinicalTrials.gov registry record
Virology Follow up Study in Subjects Previously Treated With Telaprevir
A clinical trial of Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- 408
- Enrollment target
- 20
- Study locations
NCT00916474: Completed study of Hepatitis C, sponsored by Vertex Pharmaceuticals Incorporated.
NCT00916474 is a study of Hepatitis C that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 408 participants, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00916474, a study of Hepatitis C, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- 408 participants
- Enrollment target
- 20
- Study locations
Study Summary
Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time.
Conditions Studied
Interventions
- DRUG telaprevir
Study Locations (20)
California
- California - Coronado
- California - Los Angeles
- California - San Francisco
Florida
- Florida - Gainsville
- Florida - Jacksonville
- Florida - Miami
Colorado
- Colorado - Denver
- Colorado - Englewood
New York
- New York - Manhasset
- New York - New York
North Carolina
- North Carolina - Chapel Hill
- North Carolina - Durham
Alabama
- Alabama - Birmingham
Georgia
- Georgia - Altanta
Maryland
- Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2009-06 |
| Est. Completion | 2013-12 |
What the finished NCT00916474 record still lists
NCT00916474 is an observational study that tracks outcomes without assigning an intervention. The registered 408 participants enrollment target is mid-sized for trials with a published cap, below the 1,886-participant average among 106 other Hepatitis C trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which telaprevir is the first listed.
NCT00916474 names 20 study sites across 13 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00916474 about?
NCT00916474 is a clinical study titled "Virology Follow up Study in Subjects Previously Treated With Telaprevir". Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time.
What is the current status of trial NCT00916474?
This trial is currently completed. The enrollment target is 408 participants. The study started on 2009-06. Estimated completion is 2013-12.
What conditions does trial NCT00916474 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00916474?
The interventions under investigation include: telaprevir (DRUG).
Who is sponsoring clinical trial NCT00916474?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00916474 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00916474's enrollment target sits among peer trials
408 26th of 106 higher than 81 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
RECRUITING · NA
-
Evaluation of Patients With Liver Disease
RECRUITING
-
The HOPE Study: Characterizing Patients With Hepatitis B and C
RECRUITING
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
RECRUITING · NA
-
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04835428 · 408 participants · NA
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
- NCT05836324 · 408 participants · Phase 1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
- NCT05863195 · 408 participants · Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- NCT06612268 · 408 participants · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia